# DESCRIPTION

## BACKGROUND

- introduce gonorrhea
- describe N. gonorrhoeae
- discuss limitations of current treatments

## SUMMARY

- motivate need for vaccine
- introduce peptide mimic
- describe structure of peptide mimic
- provide examples of peptide mimics
- describe antigenic peptidyl sequence
- outline embodiments of peptide mimics

## DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

- define acyl
- define alkyl
- define alkenyl
- define antibody
- define binding affinity
- explain binding affinity units
- define effective amount
- explain effective amount context
- define heteroalkyl
- define heteroaryl
- define heterocyclyl
- describe heteroalkyl groups
- describe heteroaryl groups
- describe heterocyclyl groups
- provide examples of 5-membered heteroaryl groups
- provide examples of 6-membered heteroaryl groups
- provide examples of 7-membered heteroaryl groups
- provide examples of bicyclic heteroaryl groups
- provide examples of tricyclic heteroaryl groups
- define linker
- describe linker composition
- describe linker properties
- define monoclonal antibodies
- define peptide mimic
- define leaving group
- define substituted
- describe carbon atom substituents
- describe Raa, Rbb, Rcc, Rdd, Ree, Rff, and Rgg groups
- describe protein, peptide, peptidyl sequence, and polypeptide
- describe modifications to proteins, peptides, or polypeptides
- describe production of proteins, peptides, or polypeptides
- describe recombinant protein expression and purification
- provide examples of leaving groups
- provide examples of Raa, Rbb, Rcc, Rdd, Ree, Rff, and Rgg groups
- provide references for molecular cloning and protein expression
- define percent identity
- calculate percent identity
- determine percent identity using algorithms
- define polymorph
- describe properties of polymorphs
- define salt
- describe pharmaceutically acceptable salts
- define subject
- describe treatment
- define suffix "-ene"

### CERTAIN EMBODIMENTS

- introduce LOS importance
- motivate peptide mimics
- describe peptide mimics
- define formula for peptide mimics
- specify embodiments of peptide mimics
- describe antigenic peptidyl sequence
- relate to peptide mimics with formulas
- describe immune response
- describe competition with LOS
- describe immunizing compositions
- describe methods of immunizing
- define complement protein
- describe C3d
- describe second agent
- describe carrier protein
- describe pharmaceutically acceptable composition
- describe formulations for administration
- describe administration routes
- describe dosage
- describe therapeutic applications
- describe method of modulating immune responses
- describe administration of peptide mimics
- describe timing of administration
- describe kits for modulating immune responses
- describe contents of kit
- describe instructions for use
- describe packaging
- describe examples
- describe activation of classical pathway of complement
- describe importance of complement in host defenses
- describe vaccine candidates
- describe peptide mimics elicit immunogenic response
- describe LOS purification
- outline TMCP-2 synthesis
- detail immunization of mice
- explain ELISA to measure anti-LOS antibody levels
- describe inhibition ELISA
- detail depletion of mouse IgM
- outline serum bactericidal assays
- describe mouse protection experiments
- explain statistical analyses
- characterize TMCP2
- describe choice of lead adjuvant
- detail serum bactericidal assays with IgM-depleted sera
- describe immunogenicity and bactericidal activity of anti-sera
- outline specificity of immune sera
- detail bactericidal activity of immune sera
- summarize IgG responses and bactericidal activity
- describe certain embodiments
- motivate bactericidal activity
- summarize in vitro and in vivo efficacy
- describe experimental challenge data
- discuss efficacy of TMCP2 using biweekly schedule
- discuss discussion of results
- motivate limitations of octameric peptide vaccine
- describe synthesis of TMCP2
- explain activation of classical pathway of complement
- discuss importance of complement in host defenses
- discuss immunomodulatory effects of estrogen
- motivate gonococcal vaccine development
- discuss limitations of current vaccines
- introduce 2C7 epitope and its importance
- describe LOS biosynthesis and phase variation
- discuss expression of 2C7 epitope in gonococcal isolates
- propose importance of lgtG expression for vaccine development
- introduce Tetra-MAP preparation and its limitations
- describe modular synthesis approach and peptide modifications
- discuss Click chemistry approach and its limitations
- introduce Reverse MAP synthesis and TMCP2 development
- describe immunogenicity and functional studies of TMCP2
- present example of TMCP2 vaccine efficacy in mice

## OTHER EMBODIMENTS

### Embodiment 1

- define compound of Formula (I)

### Embodiment 2

- specify A1, A2, A3, A5, A6, and A7

### Embodiment 3

- specify A1, A2, A3, A5, and A6

### Embodiment 4

- specify A1, A2, A3, A5, and A6 as glycine, proline, or cysteine

### Embodiment 5

- specify A1 as cysteine and A2, A3, A5, and A6 as glycine or proline

### Embodiment 6

- specify A7

### Embodiment 7

- specify A7 as cysteine, substituted or unsubstituted acyl, or substituted or unsubstituted alkylene

### Embodiment 8

- specify A7 as —(C═X)—CR2—

### Embodiment 9

- specify A7 as *—(C═O)—CH2—
- define Embodiment 10
- define Embodiment 11
- define Embodiment 12
- define Embodiment 13
- define Embodiment 14
- define Embodiment 15
- define Embodiment 16
- define Embodiment 17
- define Embodiment 18

